Okayama S, Tsukamoto T, Nishio A, Sakai S, Kumamoto Y
Jpn J Antibiot. 1981 Sep;34(9):1235-43.
We carried out experimental and clinical studies on tobramycin (TOB), and the following results obtained. 1. Antibacterial activity Minimum inhibitory concentration (MIC) of TOB against clinically isolated 20 strains of P. aeruginosa, E. coli, K. pneumoniae, P. mirabilis, S. marcescens and S. faecalis was determined. Except of S. marcescens, the great part of those strains were under than 25 micrograms/ml. 2. Clinical effect TOB was treated 11 patients with chronic complicated urinary tract infection in the dose of 40-60 mg twice a day for 5 days by intravenous drip infusion. Clinical effect was excellent in 2 patients, good in 4 and poor in 5, efficacy rate was 55%. In bacteriological effects, eradication rate of causative 12 strains was 67%. Side effect was not observed for all cases.
我们对妥布霉素(TOB)进行了实验和临床研究,获得了以下结果。1. 抗菌活性 测定了TOB对临床分离的20株铜绿假单胞菌、大肠杆菌、肺炎克雷伯菌、奇异变形杆菌、粘质沙雷氏菌和粪肠球菌的最低抑菌浓度(MIC)。除粘质沙雷氏菌外,这些菌株的大部分MIC低于25微克/毫升。2. 临床疗效 对11例慢性复杂性尿路感染患者采用TOB治疗,剂量为40 - 60毫克,每日两次,静脉滴注5天。2例患者临床疗效极佳,4例良好,5例较差,有效率为55%。在细菌学疗效方面,12株病原菌的根除率为67%。所有病例均未观察到副作用。